DeepCyte

Led by CEO Theodore Alexandrov, DeepCyte focuses on transforming drug development through AI-driven toxicology at single-cell resolution. Its platform combines advanced metabolomics and machine learning to detect, predict, and explain drug toxicity in human cells with unprecedented precision. The company is leveraging its proprietary technologies, including MetaCore for high-throughput single-cell metabolomics and DeeImmuno for AI-based toxicity prediction. Headquartered in Delaware and Copenhagen, DeepCyte’s mission is to reveal and prevent toxicity in every cell, at scale, before drugs reach